Jesús Martin-Garcia, CEO, GeNeuro discusses the need for new treatment approaches for multiple sclerosis (MS), a long lasting, often disabling disease of the central nervous system that affects 2.5 million people worldwide.  GeNeuro is developing a potential new approach for treating disease progression, the largest unmet medical need in MS, by seeking to block mechanisms suspected of driving neurodegeneration. #MultipleSclerosis  #MS  $GNRO GeNeuro.com